SAB Biotherapeutics Inc.
SABS | NASDAQ
$3.39
-$0.12 (-3.42%)
At close: Sep 21, 2026, 4:00 PM ET
$3.44
+$0.05 (+1.47%)
After-hours:
Sep 21, 2026, 7:30 PM ET
Company Profile
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.
Key Executives
| Name | Position |
|---|---|
| Samuel J. Reich | CEO & Director |
| Christoph Bausch | Executive Vice President & Chief Operating Officer |
| Lucy To | Executive Vice President & Chief Financial Officer |
| Alexandra Kropotova | Executive Vice President & Chief Medical Officer |
| Angie Parizek | Senior Vice President of Clinical Operations |
| Carlos N. Carillo | Senior Vice President of Regulatory Affairs |
| Catherine DeRose | Vice President of Human Resources |
| Cristi Barnett | Vice President of Investor Relations & Corporate Communications |
| Eddie Joe Sullivan | Co-Founder, President & Director |
| Hua Wu | Senior Vice President of Product Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 21, 2026 | 424B3 | Filing |
| Aug 14, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 14, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 14, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 14, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 14, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 14, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 12, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Aug 10, 2026 | SC 13D/A | [Amend] Filing |
| Aug 06, 2026 | 10-Q | Quarterly Report |
SAB Biotherapeutics Inc.
| Country | United States |
| IPO Date | Feb 8, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 86 |
| CEO | Samuel J. Reich |
Contact Details
777 W 41st St. Miami Beach,
Florida 33140 United States
Stock Details
| Ticker Symbol | SABS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001833214 |
| CUSIP Number | 78397T202 |
| ISIN Number | US78397T2024 |
| SIC Code | 2836 |
Add to Watchlist
Select watchlists to add or remove SABS